The Minority Health and Health Disparities Research and Education Act of 2000, referred to in subsec. (c), is Pub. L. 106–525, Nov. 22, 2000, 114 Stat. 2495. For complete classification of this Act to the Code, see Short Title of 2000 Amendments note set out under section 201 of this title and Tables.

2023—Subsec. (a)(2)(A). Pub. L. 117–350, § 2(a)(1)(A), inserted “, such as collected samples of both solid tumor cancer and paired samples” after “National Cancer Institute”.

Subsec. (a)(9). Pub. L. 117–350, § 2(a)(1)(B), substituted “January 5, 2023” for “June 5, 2018” in introductory provisions.

Subsec. (a)(10), (11). Pub. L. 117–350, § 2(a)(1)(C), (D), added par. (10) and redesignated former par. (10) as (11).

Subsec. (d). Pub. L. 117–350, § 2(a)(2), substituted “2024 through 2028” for “2019 through 2023”.

2018—Pub. L. 115–180, § 101(1), substituted “research, awareness, and survivorship” for “research and awareness” in section catchline.

Subsec. (a). Pub. L. 115–180, § 101(2), added subsec. (a) and struck out former subsec. (a). Prior to amendment, text read as follows:

“(1) Programs of research excellence in pediatric cancer.—The Secretary, in collaboration with the Director of NIH and other Federal agencies with interest in prevention and treatment of pediatric cancer, shall continue to enhance, expand, and intensify pediatric cancer research and other activities related to pediatric cancer, including therapeutically applicable research to generate effective treatments, pediatric preclinical testing, and pediatric clinical trials through National Cancer Institute-supported pediatric cancer clinical trial groups and their member institutions. In enhancing, expanding, and intensifying such research and other activities, the Secretary is encouraged to take into consideration the application of such research and other activities for minority, health disparity, and medically underserved communities. For purposes of this section, the term ‘pediatric cancer research’ means research on the causes, prevention, diagnosis, recognition, treatment, and long-term effects of pediatric cancer.

“(2) Peer review requirements.—All grants awarded under this subsection shall be awarded in accordance with section 289a of this title.”

Subsec. (b). Pub. L. 115–180, § 202, added subsec. (b) and struck out former subsec. (b) which related to public awareness of pediatric cancers and available treatments and research.

Subsec. (c). Pub. L. 115–180, § 101(3), struck out “(42 U.S.C. 202 note)” before period at end.

Subsec. (d). Pub. L. 115–180, § 102(b), substituted “2019 through 2023” for “2009 through 2013” and struck out “Such authorization of appropriations is in addition to the authorization of appropriations established in section 282a of this title with respect to such purpose.” before “Funds appropriated”.

Pub. L. 115–180, title I, § 121, June 5, 2018, 132 Stat. 1387, provided that: “The Director of the National Institutes of Health shall ensure that childhood cancer research projects conducted or supported by the National Institutes of Health are included in appropriate reports to Congress, which may include the Pediatric Research Initiative report.”